Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS10050536HBVENSG00000228716.7protein_codingDHFRNoNo1719B4DM58
P00374
TVIS10049990HBVENSG00000228716.7protein_codingDHFRNoNo1719B4DM58
P00374
TVIS30008799HIVENSG00000228716.7protein_codingDHFRNoNo1719B4DM58
P00374
TVIS20012134HPVENSG00000228716.7protein_codingDHFRNoNo1719B4DM58
P00374
TVIS20024726HPVENSG00000228716.7protein_codingDHFRNoNo1719B4DM58
P00374
TVIS44004386HTLV-1ENSG00000228716.7protein_codingDHFRNoNo1719B4DM58
P00374
TVIS44038861HTLV-1ENSG00000228716.7protein_codingDHFRNoNo1719B4DM58
P00374
TVIS44038892HTLV-1ENSG00000228716.7protein_codingDHFRNoNo1719B4DM58
P00374
TVIS44038891HTLV-1ENSG00000228716.7protein_codingDHFRNoNo1719B4DM58
P00374
TVIS44045060HTLV-1ENSG00000228716.7protein_codingDHFRNoNo1719B4DM58
P00374
TCGA Plot Options
Drug Information
GeneDHFR
DrugBank IDDB06813
Drug NamePralatrexate
Target IDBE0000330
UniProt IDP00374
Regulation Typesubstrate
PubMed IDs23409799
CitationsShimanovsky A, Dasanu CA: Pralatrexate : evaluation of clinical efficacy and toxicity in T-cell lymphoma. Expert Opin Pharmacother. 2013 Mar;14(4):515-23. doi: 10.1517/14656566.2013.770474. Epub 2013 Feb 14.
GroupsApproved; Investigational
Direct ClassificationGlutamic acid and derivatives
SMILESNC1=NC2=NC=C(CC(CC#C)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N=C2C(N)=N1
Pathways
PharmGKB
ChEMBLCHEMBL1201746